Review Article

Mineralocorticoid Deficiency and Treatment in Congenital Adrenal Hyperplasia

Raja Padidela¹, ² and Peter C. Hindmarsh¹, ²

¹ London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK
² Clinical and Molecular Genetics Unit, The Institute of Child Health, University College London, London WC1N 1EH, UK

Correspondence should be addressed to Peter C. Hindmarsh, p.hindmarsh@ucl.ac.uk

Received 24 January 2010; Accepted 24 February 2010

Academic Editor: Peter Allen Lee

Copyright © 2010 R. Padidela and P. C. Hindmarsh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Approximately 75%–80% of patients with Congenital Adrenal Hyperplasia (CAH) fail to synthesize sufficient mineralocorticoids to maintain salt and water balance. In most instances genotype can predict mineralocorticoid deficiency in CAH. Early recognition and replacement with 9α-fludrocortisone and salt supplements will prevent development of potentially lethal salt losing crises. In infancy a relative state of aldosterone resistance exists and replacement dose of 9α-fludrocortisone based on body surface area is higher during infancy compared to childhood and adults. Salt supplementation is generally not required after weaning is started. Regular monitoring of blood pressure and measurements of plasma electrolytes and renin are required to prevent complications of under or over dosage.

1. Introduction

Congenital adrenal hyperplasia (CAH) is a disorder of steroidogenesis in which cortisol metabolism primarily is impaired. Mineralocorticoid deficiency in CAH is a feature of 21-Hydroxylase (21-OHD), 3β-Hydroxysteroid dehydrogenase (3β-HSD) deficiencies and lipoid adrenal hyperplasia. Deficiency of 21-OHD accounts for 90% of cases of CAH [1] while deficiency of 3β-HSD, and lipoid adrenal hyperplasia are rare causes of CAH. Approximately 75% of cases of 21-OHD [1] and 60%–70% of cases of 3β-HSD deficiency [2] cannot synthesise sufficient aldosterone and are classed as “salt wasters.”

2. Genotype-Phenotype Correlation of Aldosterone Deficiency

Several studies have demonstrated strong genetic association between the degree of mineralocorticoid and glucocorticoid deficiency in 21-OHD CAH and abnormalities in the CYP21 gene [3–6]. Large gene deletions and point mutations which are expected to produce no measurable enzyme activity are associated with aldosterone deficiency and salt-wasting 21-OHD [7]. Exceptions however exist and a similar mutation can be associated with more than one phenotype giving rise to genotype-phenotype discordance [5]. The I172N CYP21 mutation is mainly associated with simple virilizing CAH but can also cause salt wasting CAH [8]. A significant difference exists between the degree of genotype-phenotype correlation demonstrated in relation to the concentration of aldosterone and that of genital phenotype [9]. The relationship with degree of virilization with genotype and aldosterone concentration is less predictable as various genetic factors regulate androgen biosynthesis and sensitivity or the ability to retain sodium through extra-adrenal mechanisms [9, 10]. A degree and spectrum of aldosterone deficiency and salt loss exists in all forms of CAH including those with simple virilising and nonclassical forms of CAH [2, 11, 12]. In clinical practice this is only relevant in very hot countries where extreme salt deprivation can manifest.

Glucocorticoids are essential for development and function of adrenal medulla and adrenomedullary function is compromised in CAH [13]. Plasma metanephrine concentration is significantly low in severe salt wasting CAH.
Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex from corticosterone by aldosterone synthetase (CYP11B2). The rate of aldosterone synthesis is 100–1000 fold less than cortisol. While cortisol circulates in the serum in nanomolar concentration, the concentration of aldosterone is 1000-fold less. Aldosterone secretion is mainly regulated by serum potassium and angiotensin II, with ACTH having only a short term effect [15].

Renin is secreted by the juxtaglomerular apparatus in response to decreased intravascular volume (Figure 1). Renin cleaves angiotensinogen into angiotensin I. Angiotensin-converting enzyme in the lungs cleaves angiotensin I to angiotensin II, a potent vasopressor agent. Angiotensin II acts through the angiotensin II receptor to hydrolyze phosphatidylinositol bisphosphate to inositol triphosphate and diacylglycerol. These raise intracellular calcium concentrations and activate protein kinase C and calmodulin-activated (CaM) kinases. Increased concentration of extracellular potassium depolarizes the cell membrane and increases calcium influx through voltage-gated calcium channels which similarly activate protein kinase C and calmodulin-activated (CaM) kinases. Phosphorylation of transcriptional regulatory factors by CaM kinases increases transcription of the aldosterone synthase (CYP11B2) gene required for aldosterone synthesis.

4. Ontogeny of Aldosterone Secretion

The renin-angiotensin-aldosterone system (RAAS) is known to be active by around 16 weeks of gestational age [16]. In the neonatal period a relative state of aldosterone resistance exists. In extreme prematurity aldosterone concentration can be as high as 12–29,000 pmol/L [17]. In term neonates the average concentration of aldosterone is 22,000 pmol/L [18] (upper limit of normal range in adult is 970 pmol/L [17]). During the first year of age, there is a steep, progressive decline in aldosterone to prepubertal concentrations [19]. The physiological basis for the relative aldosterone resistance in the neonatal period is unclear. Renal tubular immaturity leading to sodium loss could trigger the activation of RAAS alternatively impaired ability of renal tubules to respond to aldosterone action may constitute a protective mechanism against the high plasma concentration of aldosterone [18].

It is not uncommon in CAH to encounter a normal or even higher concentration of aldosterone in neonates (compared to childhood range) due to physiological resistance and possible assay interference from circulating steroids. The clue to diagnosis in these situations is the rising plasma potassium concentration which precedes the onset of hyponatremia around day 7–10 of postnatal life. These changes are associated with an increase in plasma renin activity and if left unchecked the development of a salt-losing crisis. In a recent study in healthy term neonates Martinerie et al. documented a poor correlation of serum aldosterone with serum potassium while urinary aldosterone appeared to perform better. These data if replicated suggest that spot urinary measurement of aldosterone/creatinine concentration along with plasma and urine electrolytes could be a more sensitive and better index for evaluation of mineralocorticoid effector mechanisms [18].

5. Management of Salt Loss in CAH

Most of the patients with aldosterone deficiency present in early infancy with salt loss which can be fatal if not identified and treated early. Salt loss crises classically manifest at the end of the first week of life. In girls the ambiguity of the genitalia alerts the clinician to a diagnosis of CAH at the end of the first week of life. In girls the ambiguity of the genitalia alerts the clinician to a diagnosis of CAH. Male infants present with increasing virilization and increased pigmentation of scrotum but this can be difficult to identify in early infancy which raises the chance that the actual initial presentation will be with a salt-losing crisis. Not all infants present with a salt-losing crisis and failure to thrive is another form of presentation.

Aldosterone deficiency results in excessive sodium and insufficient potassium excretion in the urine which results in hyperkalemia, hyponatremia, hypovolemia, and hyper-reninemia. Cortisol deficiency in these patients contributes to hypoglycemia, poor cardiac function, poor vascular
response to catecholamines, a decreased glomerular filtration rate, and increased secretion of antidiuretic hormone [20]. Cortisol and aldosterone deficiency together cause hypotensive dehydration and shock. Shock is further exacerbated by the deficiency of catecholamines which often accompanies salt-losing CAH [13].

The acute circulatory collapse needs intravenous resuscitation with normal saline, glucose, and intravenous hydrocortisone. In females with ambiguous genitalia and males with a family history of CAH the acute salt-losing state can be avoided by daily monitoring of the serum electrolyte concentrations in the neonatal period. The first change is an increase in the serum potassium concentration above 5.5 mmol/L and this may be associated with a serum sodium concentration in the lower quartile of the normal range or actual hyponatremia. At this point blood should be drawn for the measurement of aldosterone and plasma renin activity.

Treatment will probably be already ongoing with oral hydrocortisone (10–12 mg/m²/day, ∼3–4.5 mg/day) and 9α-fludrocortisone (150 μg/m²/day, ∼50 μg/day) with sodium supplements of up to 10–12 mmol/Kg/day (Sodium 1 mmol = 1 mEq) should be introduced. If a salt-losing crisis does not manifest in the 7–10 days of life, ongoing monitoring with twice weekly electrolytes and weekly measures of weight should be undertaken out to about 6–8 weeks of life.

Salt supplementation is required during infancy as the daily intake of milk (breast or milk formula) provides only 2 mmol/kg/day of sodium which is insufficient to replace the sodium deficit that arises in CAH. Unless there is adequate replacement of sodium simply increasing the dose of 9α-fludrocortisone will not normalize the serum sodium. Some clinicians use higher doses of 9α-fludrocortisone up to 350 μg/day [21] but the authors find that in the majority of cases a 9α-fludrocortisone dose of 150 μg/m²/day (∼50 μg/day) with salt supplements of 5–8 mmol/kg/day is sufficient. In the event of persistent hyponatremia dose of 9α-fludrocortisone is increased only after 10–12 mmol/kg/day of sodium supplements have failed to normalize the serum sodium. Care needs to be taken with high doses of 9α-fludrocortisone as the medication has dexamethasone-like glucocorticoid potency and any dose of 9α-fludrocortisone needs to be factored into the calculation of the total glucocorticoid daily dose. Once the serum sodium normalizes monitoring of serum electrolytes, blood pressure is required to titrate the dose of sodium and 9α-fludrocortisone supplements. Once weaning is fully established, by around 6–8 months of age, salt supplements are generally not required.

The dose of 9α-fludrocortisone during the first and second year of life in CAH is higher than that at other stages of life. At the point of the salt-losing crisis the requirement for a higher dose of 9α-fludrocortisone probably results from the anti-aldosterone nature of the precursors accumulated in 21-hydroxylase deficiency [22]. As the child grows, a maximum dose of 100 μg/day is usually sufficient and in adolescent and adults 50–100 μg/day is the usual requirement [23].

The half life of aldosterone is relatively short; however 9α-fludrocortisone has a longer duration of action and can usually be administered once a day although twice daily therapy with two equally divided doses is practiced [21]. This can be especially valuable approach in situations of increased physiological loss of fluid and electrolytes, for example, heat, when patients may require higher and more frequent doses of 9α-fludrocortisone [24].

CAH and its management is complicated by obesity, insulin resistance [25–27], and elevated 24-hour ambulatory arterial blood pressure measurements with absence of the nocturnal dip in blood pressure [28]. These complications place patients at significant risk for developing metabolic syndrome-related atherosclerotic cardiovascular disease in adult life [28]. For future cardiovascular health it is of paramount importance to keep the serum electrolytes and blood pressure within the normal range with the right balance of sodium supplements and 9α-fludrocortisone replacement. Overtreatment can lead to hypertension which can go unnoticed as children largely remain asymptomatic. With dexamethasone-like glucocorticoid potency of 9α-fludrocortisone, overtreatment can also impact on growth and body composition and impart insulin resistance. During the first year of life treatment with 9α-fludrocortisone is monitored by measurement of serum electrolytes along with blood pressure every 2-3 months. During the second year of life monitoring of treatment can be performed every 6 months followed by yearly in childhood and adolescence.

For the dose at which 9α-fludrocortisone is administered, drug interactions are minimal. However, caution must be taken when it is concomitantly used with antihypertensives especially those which act through RAAS pathway. 9α-fludrocortisone can potentiate the hypokalemic effects of sympathomimetics, Beta2 agonist, and theophylline especially when used with IV hydrocortisone in patients with acute severe asthma.

The need for extra mineralocorticoid replacement during stress and elective surgery is unclear. Where oral intake is possible 9α-fludrocortisone should be administered. If oral intake is not possible, the doses of intravenous hydrocortisone recommended for stressful conditions [23] often circumvent the need for 9α-fludrocortisone as the mineralocorticoid potency of 20 mg hydrocortisone is equivalent to 50 μg of 9α-fludrocortisone. Regular monitoring of serum and urine electrolytes should be undertaken with adequate intravenous substitution of sodium. Oral 9α-fludrocortisone should be commenced as soon as oral intake is feasible and gastrointestinal absorption is deemed possible.

6. Summary: Practice Points

(1) Approximately 75%–80% of patients with CAH fail to synthesize sufficient aldosterone to maintain salt balance.

(2) Early recognition and replacement with 9α-fludrocortisone and salt supplements will prevent development of potentially lethal salt losing crises.

(3) Salt supplementation is generally not required after weaning is started.
(4) Dose of aldosterone is traditionally calculated based on body surface area and is higher during infancy compared to childhood and adults.

(5) Regular monitoring of blood pressure and measurement of plasma electrolytes and renin are required to prevent complications of under or over dosage.

References

[1] P. C. White and P. W. Speiser, "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency," *Endocrinology Reviews*, vol. 21, no. 3, pp. 245–291, 2000.

[2] E. Rhéaume, J. Simard, Y. Morel, et al., "Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene," *Nature Genetics*, vol. 1, no. 4, pp. 239–245, 1992.

[3] J. Jääskeläinen, A. Levo, R. Voutilainen, and J. Partanen, "Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population," *Journal of Clinical Endocrinology & Metabolism*, vol. 82, no. 10, pp. 3293–3297, 1997.

[4] N. Krone, A. Braun, A. A. Roscher, D. Knorr, and H. P. Schwarz, "Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany," *Journal of Clinical Endocrinology & Metabolism*, vol. 85, no. 3, pp. 1059–1065, 2000.

[5] P. W. Speiser, J. Dupont, D. Zhu, et al., "Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency," *Journal of Clinical Investigation*, vol. 90, no. 2, pp. 584–595, 1992.

[6] A. Wedell, A. Thilen, E. M. Ritzen, B. Stengler, and H. Luthman, "Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation," *Journal of Clinical Endocrinology & Metabolism*, vol. 78, no. 5, pp. 1145–1152, 1994.

[7] P. C. White, M. I. New, and B. Dupont, "HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 81, no. 23, pp. 7505–7509, 1984.

[8] R. C. Wilson, A. B. Mercado, K. C. Cheng, and M. I. New, "Steroid 21-hydroxylase deficiency: genotype may not predict phenotype," *Journal of Clinical Endocrinology & Metabolism*, vol. 80, no. 8, pp. 2322–2329, 1995.

[9] F. G. Riepe and W. G. Sippell, "Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency," *Reviews in Endocrine and Metabolic Disorders*, vol. 8, no. 4, pp. 349–363, 2007.

[10] T. Huynh, I. McGown, D. Cowley, et al., "The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency," *The Clinical Biochemistry Reviews*, vol. 30, no. 2, pp. 75–86, 2009.

[11] D. B. Grant, M. J. Dillon, S. M. Atherden, and R. J. Levinsky, "Congenital adrenal hyperplasia: renin and steroid values during treatment," *European Journal of Pediatrics*, vol. 126, no. 1-2, pp. 89–96, 1977.

[12] S. Nimkarn, K. Lin-Su, N. Berglind, R. C. Wilson, and M. I. New, "Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia," *Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 1, pp. 137–142, 2007.

[13] D. P. Merke, G. P. Chrousos, G. Eisenhofer, et al., "Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency," *The New England Journal of Medicine*, vol. 343, no. 19, pp. 1362–1368, 2000.

[14] E. Charmandari, G. Eisenhofer, S. L. Mehlinger, et al., "Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency," *Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 7, pp. 3031–3037, 2002.

[15] J. Simard, M.-L. Ricketts, S. Gingras, P. Soucy, F. A. Feltus, and M. H. Melner, "Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family," *Endocrine Reviews*, vol. 26, no. 4, pp. 525–582, 2005.

[16] C.-J. Partsch, W. G. Sippell, I. Z. Mackenzie, and A. Aynsley-Green, "The steroid hormonal milieu of the undisturbed human fetus and mother at 16–20 weeks gestation," *Journal of Clinical Endocrinology & Metabolism*, vol. 73, no. 5, pp. 969–974, 1991.

[17] D. Bourchier, "Plasma aldosterone levels in the 1st week of life in infants of less than 30 weeks gestation," *European Journal of Pediatrics*, vol. 164, no. 3, pp. 141–145, 2005.

[18] L. Martinerie, E.ussard, L. Foix-L'Hélias, et al., "Physiological partial aldosterone resistance in human newborns," *Pediatric Research*, vol. 66, no. 3, pp. 323–328, 2009.

[19] W. G. Sippell, H. G. Doerr, F. Bidlingmaier, and D. Knorr, "Plasma levels of aldosterone, corticosterone, 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, cortisol, and cortisone during infancy and childhood;* Pediatric Research*, vol. 14, no. 1, pp. 39–46, 1980.

[20] S. W. J. Lamberts, H. A. Bruining, and F. H. de Jong, "Corticosteroid therapy in severe illness," *The New England Journal of Medicine*, vol. 337, no. 18, pp. 1285–1292, 1997.

[21] F. G. Kiepe, N. Krone, M. Viemann, C.-J. Partsch, and W. G. Sippell, "Management of congenital adrenal hyperplasia: results of the ESPE questionnaire," *Hormone Research*, vol. 58, no. 4, pp. 196–205, 2002.

[22] W. K. H. Oelkers, "Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure," *Studios*, vol. 61, no. 4, pp. 166–171, 1996.

[23] P. C. Hindmarsh, "Management of the child with congenital adrenal hyperplasia," *Best Practice & Research Clinical Endocrinology & Metabolism*, vol. 23, no. 2, pp. 193–208, 2009.

[24] S. Hahner and B. Allolio, "Therapeutic management of adrenal insufficiency," *Best Practice & Research Clinical Endocrinology & Metabolism*, vol. 23, no. 2, pp. 167–179, 2009.

[25] E. Charmandari, M. Weiße, S. R. Bornstein, et al., "Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications," *Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 5, pp. 2114–2120, 2002.

[26] T. M. K. Voll, D. Simm, C. Beier, and H. G. Dörr, "Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency;* Pediatrics*, vol. 117, no. 1, pp. e98–e105, 2006.

[27] R. M. Williams, A. Deeb, K. K. Ong, et al., "Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia;* Clinical Endocrinology*, vol. 72, no. 2, pp. 155–160, 2010.

[28] E. F. Roche, E. Charmandari, M. T. Dattani, and P. C. Hindmarsh, "Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report;* Clinical Endocrinology*, vol. 58, no. 5, pp. 589–596, 2003.

International Journal of Pediatric Endocrinology